QUSVM
Qiming U.S. Ventures Management Portfolio holdings
AUM
$23.6M
This Quarter Return
-5.7%
1 Year Return
-18.39%
3 Year Return
+715.34%
5 Year Return
–
10 Year Return
–
AUM
$217M
AUM Growth
–
Cap. Flow
+$217M
Cap. Flow
% of AUM
100%
Top 10 Holdings %
Top 10 Hldgs %
100%
Holding
6
New
6
Increased
–
Reduced
–
Closed
–
Top Buys
| 1 |
ICVX
Icosavax, Inc. Common Stock
ICVX
|
$80.3M |
| 2 |
Jasper Therapeutics
JSPR
|
$45.9M |
| 3 |
Tourmaline Bio
TRML
|
$44.8M |
| 4 |
Ventyx Biosciences
VTYX
|
$18.1M |
| 5 |
ELEV
Elevation Oncology
ELEV
|
$14.3M |
Top Sells
No sells this quarter
Sector Composition
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
ICVX
1
DELISTED
Icosavax, Inc. Common Stock
ICVX
| $80.3M | 36.96% | +3,510,228 | New | +$80.3M |
|
|
2
Jasper Therapeutics
JSPR
$45.5M
| $45.9M | 21.14% | +5,852,982 | New | +$45.9M |
|
|
3
Tourmaline Bio
TRML
$601M
| $44.8M | 20.63% | +2,932,606 | New | +$44.8M |
|
|
4
Ventyx Biosciences
VTYX
$171M
| $18.1M | 8.32% | +910,306 | New | +$18.1M |
|
|
ELEV
5
DELISTED
Elevation Oncology
ELEV
| $14.3M | 6.57% | +2,370,142 | New | +$14.3M |
|
6
Kezar Life Sciences
KZR
$28.9M
| $13.9M | 6.38% | +828,711 | New | +$13.9M |
|